Lutetium Lu 177 dotatate (Lutathera; Novartis) plus long-acting release (LAR) octreotidesignificantly improved progression-free survival (PFS) in patients with somatostatin receptor-positive well-differentiated grade 2/3 advanced ...
Lutetium (Lu 177) decays to stable hafnium (Hf 177) with a half-life of 6.647 days, by emitting beta radiation with a maximum energy of 0.498 MeV and photonic radiation (γ) of 0.208 MeV (11%) and 0.113 MeV (6.4%). The main radiations are detailed in Table 6. Table 6: Lu 177 ...
This targeted therapy for prostate cancer has, to date, predominately used Lutetium 177 (Lu) labelledPSMApeptides. Early clinical studies evaluating the safety and efficacy of LuPSMAtherapy have demonstrated promising results with a significant proportion of men with metastatic prostate cancer, who ...
Pluvicto (Lutetium Lu 177 Vipivotide Tetraxetan) may treat, side effects, dosage, drug interactions, warnings, patient labeling, reviews, and related medications including drug comparison and health resources.
Access more information about PLUVICTO for patients with PSMA+ metastatic castration-resistant prostate cancer (mCRPC) previously treated with ARPI and taxane therapies. See full prescribing & safety information.
The advantage of the long physical half-life (T1/2) of 177 has been utilized in mapping the pharmacokinetics of two additional agents, 177 hydroxyapatite (HA) in radiation synovectomy of knee joints and 177 for therapy of hepatocellular carcinoma. Results of these multiple studies conclusively ...
VISION is an international, prospective, randomized, open-label, multicenter, phase III study that assessed the efficacy and safety of Pluvicto (lutetium Lu 177 vipivotide tetraxetan) (7.4 GBq administered by IV infusion every 6 weeks for a maximum of 6 cycles) plus inv...
VISION is an international, prospective, randomized, open-label, multicenter, phase III study that assessed the efficacy and safety of Pluvicto (lutetium Lu 177 vipivotide tetraxetan) (7.4 GBq administered by IV infusion every 6 weeks for a maximum of 6 cycles) plus investigator-chosen standard...
This suggests the delivery of high radiation to bone metastases even from a sub-therapeutic administered activity of 500 MBq of 177Lu-PSMA-TO-1. However, higher tumor doses may present a potential for treating a patient population with bone or bone marrow lesions. Since PSMA-TO-1 is a ...
Personalized 177 Lu-octreotate peptide receptor radionuclide therapy of neuroendocrine tumours: a simulation study. Eur J Nucl Med Mol Imaging. 2017;44:1490–500. Article PubMed Google Scholar Spiers F. A review of the theoretical and experimental methods of determining radiation dose in bone. ...